The research company Cantargia has appointed Monic Stuart as Chief Medical Officer with immediate effect. She will lead the clinical development of nadunolimab in blood cancers and solid tumors.
Stuart has more than 20 years of experience in drug development in oncology and has held senior roles at, among others, Acerta Pharma, Genentech, Geron and Revolution Medicines. She has also served as an adviser in clinical development to around 35 companies globally.
